Malignant Solid Neoplasm

114

Review clinical trials related to Malignant Solid Neoplasm. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.

Participants needed: 70
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: National Cancer Institute (NCI)Updated: Jul 13, 2026Locations: 188
Eligibility criteria

Patient must have enrolled onto EAY191 and must have been given a treatment assi... [+34]

Status: Not yet recruiting

Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors

This clinical trial tests how well a type of non-invasive brain stimulation called transcranial direct current stimulation (tDCS) works to treat chemotherapy induced peripheral neuropathy (CIPN) in cancer survivors. CIPN is numbness, tingling, pain, and movement problems that can develop after chemotherapy as a result of changes to the nerves. A non-invasive form of brain stimulation called tDCS, applied to the area of the brain involved in sensation and movement, can temporarily improve the ability to detect vibration and temperature, as well as balance and walking, which may improve sensation and reduce pain in cancer survivors with CIPN.

Participants needed: 50
Trial details
Age: 18-85Biological sex: AllType: InterventionalSponsor: University of Michigan Rogel Cancer CenterUpdated: Jul 13, 2026Locations: 1
Eligibility criteria

18 to 85 years of age [+6]

Known brain metastases [+10]

Status: Recruiting

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.

Participants needed: 70
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: National Cancer Institute (NCI)Updated: Jul 2, 2026Locations: 188
Eligibility criteria

Patient must have enrolled onto EAY191 and must have been given a treatment assi... [+34]

Status: Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Participants needed: 2,000
Trial details
Age: 40-75Biological sex: AllType: ObservationalSponsor: Alliance for Clinical Trials in OncologyUpdated: Jul 2, 2026Locations: 745
Eligibility criteria

Histologic documentation: Histologically confirmed diagnosis of invasive cancer [+47]

Status: Recruiting

The Vanguard Study: Testing a New Way to Screen for Cancer

The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).

Participants needed: 24,000
Trial details
Age: 45-75Biological sex: AllType: InterventionalSponsor: National Cancer Institute (NCI)Updated: Jul 1, 2026Locations: 38
Eligibility criteria

Ages 45-75 years old [+4]

Solid malignant tumor or blood cancer diagnosis, with or without treatment, with... [+4]

Status: Recruiting

Optimizing Health Related Quality of Life Measurement in Adolescent and Young Adult Oncology

This study evaluates how adolescent and young adults with cancer in the U.S. and their loved ones respond to questions that will later be used with people who may have cancer and other chronic health conditions

Participants needed: 3,000
Trial details
Age: 15+Biological sex: AllType: ObservationalSponsor: Wake Forest University Health SciencesUpdated: Jun 30, 2026Locations: 1
Eligibility criteria

Young adults between the ages of 15 to 39 years; [+4]

Diagnosed with basal cell skin cancer; or [+9]

Status: Recruiting

Virtual Reality for Symptom Management in Patients Undergoing Hematopoietic Stem Cell Transplantation

This clinical trial compares the use of virtual reality to standard care for improving symptom management in patients undergoing hematopoietic stem cell transplantation (HSCT). Significant symptoms experienced by hospitalized HSCT patients include, but are not limited to, depression, tiredness, anxiety, drowsiness, lack of appetite, pain, and overall decreased quality of life and well-being. Virtual reality (VR) as an intervention can provide these patients with a much-needed escape from their reality and has proven results in clinical settings as a distraction therapy. VR technology targets the patient's auditory, visual, and physical contact/touch senses, and has been evidenced to improve depression, fatigue, anxiety, appetite, and pain. Virtual reality may improve symptom management in patients undergoing HSCT.

Participants needed: 28
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Roswell Park Cancer InstituteUpdated: Jun 30, 2026Locations: 1
Eligibility criteria

Adult patients (≥ 18 years old) admitted to Roswell Park on 5 North for planned... [+3]

Participants with known brain metastases should be excluded from this clinical t... [+6]

Status: Recruiting

Comparing the Impact of Four Types of Meditation Practices for Relaxation in Cancer Survivors

This clinical trial compares the impact of four types of meditation practices, breathing only, focused attention only, mindfulness only, and breathing, focused attention and mindfulness combined, for relaxation in cancer survivors. Studies show that many patients with cancer experience stress and anxiety. Meditation therapy uses a variety of techniques, such as breathing, sound, or movement, that may help to decrease distress and anxiety and enhance the health and quality of life of patients with cancer. The trial is being done to find out how meditation can help cancer survivors feel relaxed and attain a peaceful state of mind.

Participants needed: 44
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: City of Hope Medical CenterUpdated: Jul 1, 2026Locations: 2
Eligibility criteria

Documented written informed consent of the participant [+8]

Inability to complete study required time and procedures as outlined in the stud... [+5]

Status: Not yet recruiting

Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors

This clinical trial tests how well a type of non-invasive brain stimulation called transcranial direct current stimulation (tDCS) works to treat chemotherapy induced peripheral neuropathy (CIPN) in cancer survivors. CIPN is numbness, tingling, pain, and movement problems that can develop after chemotherapy as a result of changes to the nerves. A non-invasive form of brain stimulation called tDCS, applied to the area of the brain involved in sensation and movement, can temporarily improve the ability to detect vibration and temperature, as well as balance and walking, which may improve sensation and reduce pain in cancer survivors with CIPN.

Participants needed: 50
Trial details
Age: 18-85Biological sex: AllType: InterventionalSponsor: University of Michigan Rogel Cancer CenterUpdated: Jun 29, 2026Locations: 1
Eligibility criteria

18 to 85 years of age [+6]

Known brain metastases [+10]

Status: Recruiting

A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors Post-treatment

This clinical trial studies whether a virtually delivered diet intervention focused on lower added sugar, higher fiber, and higher omega 3 fatty acid (LASO-3) can be used to improve chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors after treatment. Cancer survivors often experience CIPN during and after cancer treatment with neurotoxic chemotherapy. CIPN is characterized by nerve damage from chemotherapy that leads to numbness, tingling, or pain in the hands or feet. However, there are few treatments to manage CIPN. Inflammation contributes to the development of CIPN and dietary patterns that have been demonstrated to improve diet quality and reduce inflammation in cancer survivors may be promising for use as a CIPN management strategy. The LASO-3 diet intervention consists of virtually delivered nutrition education sessions provided by a Registered Dietitian. The sessions focus on three dietary goals, informed by the United States Dietary Guidelines for Americans: 1) lowering added sugar intake to \< 10% of daily calories, 2) increasing daily fiber intake to ≥ 20 grams, and 3) increasing intake of moderate-high omega-3 seafood to three or more servings weekly or 3300-3400 mg/day of alpha-linolenic acid (e.g., plant-based sources include canola or flaxseed oil, walnuts, or flaxseed or chia seeds). The Registered Dietitian tailors the sessions to the patient based on information and feedback obtained throughout the sessions. The LASO-3 diet intervention may be an effective way to improve CIPN in cancer survivors after treatment.

Participants needed: 50
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of Michigan Rogel Cancer CenterUpdated: Jun 25, 2026Locations: 1
Eligibility criteria

18 years or older [+4]

Pre-existing peripheral neuropathy from any cause [+6]

Status: Recruiting

Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment

In this clinical trial, symptom monitoring (interactive voice response \[IVR\] is compared to automated telephone symptom management \[ATSM\] and telephone interpersonal counseling \[TIPC\]) for reducing symptom burden and psychological distress (depressive and anxiety symptoms) among people receiving oral anti-cancer treatment. Symptoms are the number one driver of treatment interruptions and unscheduled health services use. To reduce the risk of these events, symptom monitoring and management are necessary. However, these services are not implemented routinely, especially in the community oncology settings. Further, depressive and anxiety symptoms are a key barrier to enacting symptom self-management strategies. IVR is a form of symptom monitoring where patients, when called, enter their symptom ratings over the phone. Their symptom summary is sent to their provider, and patients may be advised to reach out to their oncology provider, based on their symptoms. The ATSM intervention combines IVR assessments with a Symptom Management and Survivorship educational handbook with self-management strategies. Patients receiving ATSM enter their symptom ratings over the phone and have their symptoms reported to their provider, but patients are also directed to the handbook for strategies to manage elevated symptoms. Patients receiving ATSM who report being anxious, discouraged, or sad will also receive TIPC, which targets psychological distress and its connection to social support and interpersonal communication. Information gathered from this study may help researchers learn more about the best ways to manage patient symptoms and improve patient outcomes.

Participants needed: 600
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: NRG OncologyUpdated: Jun 25, 2026Locations: 34
Eligibility criteria

PRACTICES: All institutions participating in the practice are National Cancer In... [+16]

PRACTICES: Active telephone symptom management program at the practice that is b... [+4]

Status: Recruiting

Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer

This study evaluates how useful and acceptable the components of the "Couples Coping Together Against Cancer", referred to as "The Program", are to the participants with cancer.

Participants needed: 160
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: City of Hope Medical CenterUpdated: Jun 24, 2026Locations: 1
Eligibility criteria

Have received a diagnosis of a primary brain tumor (glioblastoma), or other canc... [+5]

Significant cognitive impairment [+5]

Status: Recruiting

A Mindfulness-Based Stress Reduction Program for Improving Mental Health Outcomes for Underserved Cancer Patients in Minnesota

This clinical trial evaluates whether a virtual stress reduction program that uses mindfulness-based stress reduction (MBSR) techniques works to improve mental health outcomes in cancer patients living in underserved/rural regions of Minnesota. 80% of Minnesota counties are considered mental health care shortage areas. This shortage disproportionately impacts Minnesotans living in underserved and rural regions as they have to travel further for mental health care services. Interventions that provide patients with mental health resources from the comfort of their own home help to reduce barriers that limit access to mental health care. MBSR courses can help patients control their responses to stressful events, reduce the impact of chronic stress, develop more effective ways to cope with medical/psychological conditions, and increase overall sense of well-being. MBSR courses may serve as a way to bridge the gap between mental health care and patients with cancer living in underserved/rural regions of Minnesota.

Participants needed: 45
Trial details
Biological sex: AllType: InterventionalSponsor: Mayo ClinicUpdated: Jun 23, 2026Locations: 1
Eligibility criteria

Patients with a history of cancer, or currently have cancer [+4]

Non-English-speaking patients [+2]

Status: Not yet recruiting

Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids

This phase II trial studies whether psilocybin with psychotherapy is safe and if it works for improving chronic pain in cancer patients who require opioids to manage their pain. Psilocybin is taken from the mushroom Psilocybe mexicana. Psilocybin acts on the brain to cause hallucinations (sights, sounds, smells, tastes, or touches that a person believes to be real but are not real). This may impact a patient's "total pain", a view that accounts for the psychological, spiritual, and social factors that contribute to their experience of pain. Psychotherapy uses methods such as discussion, listening, and counseling to help patients change the way they react to environmental triggers that may cause a negative reaction. Giving psilocybin with psychotherapy may be safe and helpful for improving chronic pain in cancer patients who require opioids to manage their pain.

Participants needed: 20
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Roswell Park Cancer InstituteUpdated: Jun 22, 2026Locations: 1
Eligibility criteria

Age ≥ 18 and ≤ 75 years old [+21]

Participants who are pregnant or breast-feeding [+29]

Status: Recruiting

Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events

This study is being done to find out if patient blood samples can be used to perform individualized modeling of cancer therapy-related side effects.

Participants needed: 30
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Mayo ClinicUpdated: Jun 23, 2026Locations: 1
Eligibility criteria

Any patient >= 18 years of age [+1]

Inability on the part of the patient to understand the informed consent or be co...

Status: Recruiting

Virtual Reality Viewing of Unaltered Streetscape Versus Digitally Manipulated Opposite Streetscape to Assess Psychosocial Response in Participants

This clinical trial compares virtual reality viewing of an unaltered streetscape versus a digitally manipulated opposite streetscape to assess the psychosocial response in participants. Visible measures of neighborhood factors might be associated with health outcomes and risk factors of those outcomes. Short-term exposure to virtual reality environments representing very high or very low levels of neighborhood physical disorder - presence or absence of garbage/litter, presence or absence of graffiti, presence or absence of an abandoned building, presence or absence of large dumpsters, poor or very well-kept building conditions, poor or very well-kept yard conditions, poor or very well-kept road verge conditions may be a safe and effective way to assess psychosocial response in participants.

Participants needed: 32
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Ohio State University Comprehensive Cancer CenterUpdated: Jun 22, 2026Locations: 1
Eligibility criteria

Adults 18+ [+6]

Pregnant women [+2]

Status: Not yet recruiting

Cannabis Gummy for the Improvement of Sleep and Quality of Life in Patients With Cancer, Pillow Trial

This clinical trial tests how well a cannabis gummy works in improving sleep and quality of life in patients with cancer. Many people with cancer (about 60%) have trouble sleeping, which can lower their quality of life. Sleep disturbance is defined as difficulty initiating or maintaining sleep, waking up earlier than desired and being unable to fall back to sleep, and excessive daytime sleepiness. In adults with cancer, sleep disturbance may be caused by multiple, often co-occurring factors including diagnosis, type, and stage of cancer, treatment regimen, physical complaints (e.g., pain), and psychological distress. Some patients use cannabis to help with sleep, but its effects are not well understood. Cannabis, which some people call marijuana, refers to the dried leaves, flowers, stems, and seeds of the cannabis sativa L plant. The plant contains at least 125 different cannabinoids, including delta-9 tetrahydrocannabinol (THC). Delta-9 THC is the most abundant form of THC in the cannabis plant. It has intoxicating effects, meaning it can temporarily alter a person's mood, thoughts, and perceptions (a "high"). This study will help researchers learn how cannabis affects sleep and quality of life compared to usual care.

Participants needed: 50
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Theodore Brasky PhDUpdated: Jun 22, 2026Locations: 1
Eligibility criteria

New patients in the OSUCCC's Palliative Care clinics who have histologically or... [+2]

patients taking checkpoint inhibitors and investigational agents will not be eli... [+39]

Status: Recruiting

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients. Many cancer patients experience financial hardship due to high medical out of pocket costs (OOPC), changes in employment, income and insurance. Financial hardship can lead to a delay or a stop in cancer care, and is linked to poor quality of life. Financial navigation programs, such as CostCOM, provide financial counseling, education and connections to appropriate resources to reduce financial barriers to healthcare and minimize financial stress and burden. CostCOM may improve adherence to care and decrease financial burden in patients with cancer.

Participants needed: 760
Trial details
Biological sex: AllType: InterventionalSponsor: ECOG-ACRIN Cancer Research GroupUpdated: Jun 18, 2026Locations: 392
Eligibility criteria

NON-PATIENTS PARTICIPANTS: Participant must speak English [+28]

Status: Recruiting

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced), to other places in the body (metastatic) or cannot removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Cabozantinib is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor. Chemotherapy drugs, such as platinum containing therapies and fluoropyrimidine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab alone and in combination with other treatments, including ipilimumab, cabozantinib, platinum containing therapy, or fluoropyrimidine, may be safe, tolerable, and/or effective in treating patients with autoimmune disorders and advanced, metastatic, or unresectable cancer.

Participants needed: 300
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: National Cancer Institute (NCI)Updated: Jun 17, 2026Locations: 52
Eligibility criteria

Patients can have either histologically confirmed malignancy that is radiologica... [+53]

Repeat imaging demonstrates no new sites of bone metastases [+13]

Status: Recruiting

Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors

This phase III trial studies the side effects and how well stereotactic radiosurgery (SRS) works before or after surgery in patients with tumors that has spread to the brain or that can be removed by surgery. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.

Participants needed: 140
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Mayo ClinicUpdated: Jun 16, 2026Locations: 4
Eligibility criteria

Age >= 18 years [+6]

Pregnant women [+16]

Status: Recruiting

Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion

This study investigates whether alteplase can help to improve pleural fluid drainage and dyspnea (breathlessness) in patients with non-draining malignant pleural effusion. Alteplase helps dissolve blood clots and is used to treat heart attacks, strokes, and clots in the lungs. Alteplase may help to control symptoms of breathlessness.

Participants needed: 30
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 12, 2026Locations: 1
Eligibility criteria

Referral to pulmonary services for inability to drain fully via IPC [+8]

Inability to provide informed consent [+7]

Status: Recruiting

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself. This may help researchers develop methods to predict the risk of side effects for future patients and learn the long-term benefit of proton therapy.

Participants needed: 5,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 12, 2026Locations: 1
Eligibility criteria

All patients scheduled for radiation treatment with protons at UTMDACC are eligi... [+1]

Patients who are unable or unwilling to attend the required periodic follow-ups...

Status: Recruiting

Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases

This clinical trial studies the effect of respiratory training for enhancing brain and mental health among patients with multiple sclerosis (MS) and cancer (along with their caregivers). The relationship between respiration, cardiovascular effects in the brain, mental health, and neurophysiological mechanisms are significant for patient populations facing complex health challenges, such as those with cancer and neurodegenerative disease, and their caregivers. By measuring oxygen delivery to brain tissues and cerebrospinal fluid flow, this trial may help researchers investigate the potential benefits of respiratory training for patients with MS and cancer and their caregivers.

Participants needed: 147
Trial details
Age: 18-85Biological sex: AllType: InterventionalSponsor: Mayo ClinicUpdated: Jun 10, 2026Locations: 1
Eligibility criteria

STUDY 1: Participants must be physically fit enough to perform light exercise. [+11]

STUDY 1: Participants incompatible with MRI machines due to factors such as pace... [+9]

Status: Recruiting

Increasing Knowledge and Interest in Cancer Clinical Trials

This trial investigates how well a video-based clinical trial education session works in increasing knowledge and interest in cancer clinical trials among individuals in the metropolitan Detroit region of the Karmanos Cancer Institute (KCI) catchment area. This educational activity may help researchers learn more about individuals' awareness of clinical trials, knowledge, and intention to participates in a clinical trial.

Participants needed: 384
Trial details
Age: 21+Biological sex: AllType: InterventionalSponsor: Hayley ThompsonUpdated: Jun 10, 2026Locations: 1
Eligibility criteria

Individuals aged 21 and older [+3]

none

Status: Recruiting

Ex Vivo Expansion (ACT-X)

The purpose of this study is to understand how the body's immune cells respond to a new type of vaccine (neoantigen vaccine) designed to help the immune system recognize and fight cancer. To do this, the study team will collect a research specimen from participants to study their immune cells' reactions to the neoantigen vaccine. This research will help researchers learn more about how these vaccines might work to protect or treat against cancer.

Participants needed: 24
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Mayo ClinicUpdated: Jun 9, 2026Locations: 1
Eligibility criteria

Histologically confirmed current or previous solid malignancy or healthy individ... [+6]

IV antibiotic ≤2 weeks prior to apheresis [+9]